{"status": "Ok", "redirect_url": "https://neurosense.investorroom.com/2026-06-29-NeuroSense-Achieves-Primary-Endpoint-in-Phase-2b-ALS-Study-with-Statistically-Significant-Reduction-of-TDP-43,-the-Defining-Pathological-Hallmark-of-ALS", "message": "News view counter 820683 successfully enlarged"}